NIOX vs. SN, MXCT, EKF, IUG, CREO, NCYT, POLX, IHC, AVO, and RUA
Should you be buying NIOX Group stock or one of its competitors? The main competitors of NIOX Group include Smith & Nephew (SN), MaxCyte (MXCT), EKF Diagnostics (EKF), Intelligent Ultrasound Group (IUG), Creo Medical Group (CREO), Novacyt (NCYT), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), and RUA Life Sciences (RUA). These companies are all part of the "medical devices" industry.
NIOX Group vs.
Smith & Nephew (LON:SN) and NIOX Group (LON:NIOX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment.
Smith & Nephew received 557 more outperform votes than NIOX Group when rated by MarketBeat users. However, 100.00% of users gave NIOX Group an outperform vote while only 62.02% of users gave Smith & Nephew an outperform vote.
NIOX Group has lower revenue, but higher earnings than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.
62.2% of Smith & Nephew shares are owned by institutional investors. Comparatively, 35.2% of NIOX Group shares are owned by institutional investors. 0.2% of Smith & Nephew shares are owned by company insiders. Comparatively, 46.7% of NIOX Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
NIOX Group has a net margin of 28.21% compared to Smith & Nephew's net margin of 5.41%. NIOX Group's return on equity of 13.29% beat Smith & Nephew's return on equity.
Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.9%. NIOX Group pays an annual dividend of GBX 1 per share and has a dividend yield of 1.7%. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 4,126.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew is clearly the better dividend stock, given its higher yield and lower payout ratio.
Smith & Nephew has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, NIOX Group has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
Smith & Nephew currently has a consensus price target of GBX 4,607.50, indicating a potential upside of 368.43%. NIOX Group has a consensus price target of GBX 90, indicating a potential upside of 53.13%. Given Smith & Nephew's higher probable upside, research analysts clearly believe Smith & Nephew is more favorable than NIOX Group.
In the previous week, NIOX Group had 8 more articles in the media than Smith & Nephew. MarketBeat recorded 8 mentions for NIOX Group and 0 mentions for Smith & Nephew. NIOX Group's average media sentiment score of 0.02 beat Smith & Nephew's score of 0.00 indicating that NIOX Group is being referred to more favorably in the news media.
Summary
NIOX Group beats Smith & Nephew on 10 of the 19 factors compared between the two stocks.
Get NIOX Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for NIOX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart
NIOX Group Competitors List
Related Companies and Tools
This page (LON:NIOX) was last updated on 4/18/2025 by MarketBeat.com Staff